Mood Stabilizers during Pregnancy: Clinical Updates
Based on current data of in utero exposure to mood stabilizers, valproic acid (Depakene, Depakote, and others) and carbamazepine (Tegretol and others) present the greatest risk for adverse long-term neurobehavioral outcomes, whereas lithium and lamotrigine (Lamictal and others) so far appear to be safe. Antipsychotics have not been adequately studied.
Ongoing Treatment for BDD
Of patients with body dysmorphic disorder who respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), those who are continued on SSRI treatment for 6 months show greater improvement and longer time to relapse than those switched to placebo.
FDA Removes Black Box Warning for Smoking Cessation Drugs Varenicline and Bupropion; Low Levels of Brain-Derived Neurotrophic Factor Decrease Depressed Patients Response to Chemotherapy
Antihypertensives and the Risk of Mood Disorders
In a Scottish retrospective study, patients who took angiotensin antagonist antihypertensive medications had a lower risk of being admitted to the hospital for a mood disorder than those who did not.
About the BTP Newsletter
Our subscribers say BTP is…
"Very relevant, practical, and thought-provoking."
"About the only thing left without drug ads...objective and balanced."
"Succinct, readable, clear, timely and relevant!"
"Well written and scientifically sound."
Originating at the Massachusetts General Hospital and Harvard Medical School, Biological Therapies in Psychiatry has been a trusted resource for physicians for over 30 years. Described as "influential" by the Atlantic Monthly, this concise, four-page, monthly newsletter provides up-to-date information about the rapidly expanding field of psychotropic medications and other biological treatments for mental disorders.
From his perspective as an editor, teacher, investigator, and clinician, Alan J. Gelenberg, M.D., reviews the widespread literatures of science and clinical practice. Dr. Gelenberg distills the material most relevant for a busy practitioner and presents it each month with a balance of scientific curiosity, healthy skepticism, and clinical experience.
Dr. Gelenberg is Professor and Interim Chair of Psychiatry at Penn State, Hershey. Since 1987, Dr. Gelenberg has been Editor-in-Chief of the Journal of Clinical Psychiatry, and he recently chaired the workgroup that revised the American Psychiatric Association's major depressive disorder guidelines. Dr. Gelenberg has been on the faculty of Harvard Medical School, MIT, and the University of Arizona and has written numerous scientific articles and book chapters on mood disorders, depression, and schizophrenia. He is listed in the Best Doctors in America and America's Top Doctors and received the 1997 Exemplary Psychiatrist Award of the National Alliance for the Mentally Ill.
We offer both print and online subscriptions. Our web site provides subscribers with 24-hour access to archives as well as current issues. In addition, Continuing Medical Education credit is available for reading BTP. You can earn up to 12.0 hours in category 1 credit by answering questions in the December issue about topics covered during the year.